中药联合环磷酰胺治疗结缔组织病相关间质性肺病的Meta分析
本Meta分析纳入7项随机对照试验共506例结缔组织病相关间质性肺病患者,评估中药联合环磷酰胺的疗效与安全性。结果显示联合治疗可提高临床有效率(RR=1.21),改善多项肺功能指标,降低HRCT积分和ESR,且不增加不良事件。但样本量较小,结论需更大规模试验证实。
要点
- 中药联合环磷酰胺可提高CTD-ILD临床有效率(RR=1.21,95%CI 1.09–1.35)。
- 联合治疗改善VC、FVC、FEV1、TLC、DLCO、MVV等肺功能指标。
- 联合治疗降低HRCT积分和ESR,且不增加不良事件发生率。
核心结论
- 中药联合环磷酰胺可能对结缔组织病相关间质性肺病是更有效的治疗策略。
- 因纳入研究样本量较小,结果需更多设计良好、大规模随机对照试验证实。
研究设计与样本
- 研究类型为Meta分析,检索10个数据库中中药治疗结缔组织病相关间质性肺病的随机对照试验。
- 共纳入7项随机对照试验,506例参与者,采用Cochrane协作工具进行方法学质量评估。
- 数据分析使用RevMan v5.3和Stata v14.0软件,遵循PRISMA清单。
主要发现
- 临床有效率:RR=1.21,95%CI(1.09,1.35),p=0.0003。
- 肺功能VC:WMD=9.49,95%CI(5.54,13.45),p<0.00001;FVC:SMD=0.83,95%CI(0.36,1.29),p=0.0005。
- FEV1:SMD=0.54,95%CI(0.23,0.86),p=0.0008;TLC:SMD=0.90,95%CI(0.68,1.13),p<0.00001。
- DLCO:SMD=1.05,95%CI(0.38,1.73),p=0.002;MVV:SMD=0.83,95%CI(0.50,1.17),p<0.00001。
- HRCT积分:SMD=-2.02,95%CI(-3.14,-0.91),p=0.0004;ESR:WMD=-13.33,95%CI(-18.58,-8.09),p<0.00001。
关键数值与推荐
- 临床有效率RR=1.21(95%CI 1.09–1.35,p=0.0003)。
- VC的WMD=9.49(95%CI 5.54–13.45,p<0.00001)。
- FVC的SMD=0.83(95%CI 0.36–1.29,p=0.0005)。
- HRCT积分SMD=-2.02(95%CI -3.14至-0.91,p=0.0004)。
- ESR的WMD=-13.33(95%CI -18.58至-8.09,p<0.00001)。
临床怎么用
- 对于结缔组织病相关间质性肺病患者,可考虑中药联合环磷酰胺以改善临床有效率和肺功能。
- 联合治疗可能降低HRCT积分和ESR,且不增加不良事件,但需结合患者个体情况。
- 现有证据样本量较小,临床应用时应谨慎,并关注后续更大规模试验结果。
局限性
- 纳入研究样本量相对较小。
- 结果需更多设计良好、大规模随机对照试验确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objectives: To evaluate the effectiveness and safety of Chinese herbal medicines (CHMs) combined with cyclophosphamide (CTX) for connective tissue disease-associated interstitial lung disease (CTD-ILD) by performing a meta-analysis. Methods: We searched RCTs of Chinese herbal medicines therapy for connective tissue disease-associated interstitial lung disease in ten databases. Methodological quality assessment was performed by the Cochrane collaboration tool. RevMan v5.3 and Stata v14.0 software were used for performing data analysis. This study was conducted and reported following the PRISMA checklist. Results: Overall, seven RCTs with 506 participants were included for this analysis. Current data indicated that Chinese herbal medicines combined with cyclophosphamide contributed to a betterment in improving the clinical efficacy rate of connective tissue disease-associated interstitial lung disease [risk ratio (RR) = 1.21, 95% confidence interval (CI): (1.09, 1.35), p = 0.0003], tended to benefit improvement of lung function, which included VC [weighted mean difference (WMD) = 9.49, 95% CI: (5.54, 13.45), p < 0.00001], FVC [standardized mean difference (SMD) = 0.83, 95% CI: (0.36, 1.29), p = 0.0005], FEV1 [SMD = 0.54, 95% CI: (0.23, 0.86), p = 0.0008], TLC [SMD = 0.90, 95% CI: (0.68, 1.13), p < 0.00001], DLCO [SMD = 1.05, 95% CI: (0.38, 1.73), p = 0.002], and MVV [SMD = 0.83, 95% CI: (0.50, 1.17), p < 0.00001], and it also could significantly reduce the HRCT integral of lungs [SMD = -2.02, 95% CI: (-3.14, -0.91), p = 0.0004] and the level of ESR [WMD = -13.33, 95% CI: (-18.58, -8.09), p < 0.00001]. Furthermore, there was no statistical significance in the incidence of adverse events (AEs), which indicate that Chinese herbal medicines combined with cyclophosphamide is safe and does not increase adverse events compared with cyclophosphamide alone. Conclusion: Our analysis indicates that Chinese herbal medicines combined with cyclophosphamide may be a more effective strategy on the treatment of connective tissue disease-associated interstitial lung disease in the clinic. Because it included studies with relatively small sample size, the results need to be confirmed by more well-designed and large-scale RCTs. Systematic Review Registration: https://10.37766/inplasy2022.12.0010.
引用
- Yin X, Zhao S, Xiang N, et al. Efficacy and safety of Chinese herbal medicines combined with cyclophosphamide for connective tissue disease-associated interstitial lung disease: A meta-analysis of randomized controlled trials. Front Pharmacol. 2023. PMID: 36909152. doi:10.3389/fphar.2023.1064578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。